about
Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.Improved utilization of ADAS-cog assessment data through item response theory based pharmacometric modeling.Plasma and cerebrospinal fluid pharmacokinetics of flurbiprofen in children.Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers.Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurementsMultinomial logistic functions in markov chain models of sleep architecture: internal and external validation and covariate analysis.Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.Automated identification of axonal growth cones in time-lapse image sequences.Population pharmacometrics in support of analgesics studies.Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014)Preconditioning of Nonlinear Mixed Effects Models for Stabilisation of Variance-Covariance Matrix ComputationsMaturation of Oxycodone Pharmacokinetics in Neonates and Infants: a Population Pharmacokinetic Model of Three Clinical Trials.Accelerating Monte Carlo power studies through parametric power estimation.Optimal design in population kinetic experiments by set-valued methods.A diagnostic tool for population models using non-compartmental analysis: The ncappc package for R.The effect of using a robust optimality criterion in model based adaptive optimization.Estimation of drug receptor occupancy when non-displaceable binding differs between brain regions – extending the simplified reference tissue modelModeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose.Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members.Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development.Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.The effect of Fisher information matrix approximation methods in population optimal design calculations.Model Description Language (MDL): A Standard for Modeling and Simulation.Chain length of dietary alkylresorcinols affects their in vivo elimination kinetics in rats.Joint modeling of efficacy, dropout, and tolerability in flexible-dose trials: a case study in depression.Optimal experimental design for assessment of enzyme kinetics in a drug discovery screening environment.Methodological comparison of in vitro binding parameter estimation: sequential vs. simultaneous non-linear regression.Optimizing disease progression study designs for drug effect discrimination.A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066 - estimating occupancy in the absence of a reference region.An evaluation of population D-optimal designs via pharmacokinetic simulations.Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model.Simultaneous optimal experimental design for in vitro binding parameter estimation.Evaluation of bias, precision, robustness and runtime for estimation methods in NONMEM 7.Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design.Simultaneous optimal experimental design on dose and sample times.Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier.Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection.Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes.Plasma and cerebrospinal fluid pharmacokinetics of naproxen in children.Adaptive-optimal design in PET occupancy studies.
P50
Q30499990-35ED1A94-07C4-467C-829F-3FEF9163D684Q30770186-BE155113-7B85-4CF0-9A55-1AB0F85A83FBQ34180474-936CAB45-2E9F-467A-B816-9FAD97751408Q34198755-901DEA4D-605B-4EED-AF0D-C29209E5DC84Q34974275-78745CFC-49D2-48C8-9869-2FCEC3EB87B7Q35176909-0C2828AD-7B1B-49AE-97D6-2BA03A7466C9Q36203402-16296E13-9156-4069-BF50-37A23CB625EBQ37360185-9962048D-E259-46FA-BAE8-62A326F50503Q38175171-41803882-3ADC-417A-B94B-BB1BD4F15174Q38672541-CB607CD1-08F9-40BB-8C5D-AC6B0C0E4EA5Q38790640-266E409D-529F-4111-8512-C0425570B8AAQ38958587-B7394FDE-9396-4BE5-B417-A67793E55EC4Q38996531-B98C9B83-C1A0-4B14-B192-AFE26F1CDB15Q39636200-DBFF3885-4C29-426E-A420-8670A9B3D60DQ39901037-2CD35FDF-AE8B-4C31-B429-C98F93DD5135Q41039742-BEAD73DA-4A15-4DBB-9A64-CC647CFC5AEBQ41368809-8643FB60-F278-45FA-BDEA-6EEF43ABD241Q41454681-ED796C99-A730-4B49-9ACC-F1F8E85370E4Q41454771-2237DCC5-C612-4E6D-A259-B874BA207536Q41994917-AF83EB4A-F911-44DF-9F7F-EACF2DE0D3C6Q42236437-D4BEE416-F388-4A54-ACB4-1E6F2788468BQ42368317-5300133A-9E16-4029-AC6B-A2F16D2C780EQ42621642-D88FB022-B1C2-432E-A5C2-C5FFD6AEA29FQ43451894-A2A730A0-1E1A-4425-B2AF-07E0EBC69890Q43457571-44CFF628-FA27-4FCC-B81C-9EE3C4EDFD09Q43462180-27EEBB2F-7207-49B5-AEF4-461639D325DCQ43771061-DEB7B0CA-27D3-4288-AA63-E62C6075564CQ43837566-6D2E4903-5C38-40EB-8C4A-1A8053E1CEEAQ44208884-9A1F82B2-44BD-4F17-8830-5A9BD4885D3DQ44305634-27A6F5CC-DB25-4C5C-A543-D6916513AAEBQ44643857-EFCCBE3A-94F2-496C-B88C-9BB672A444DCQ44771007-4B563AF1-7A2C-4E3B-8CE3-84813275870FQ45011333-F172C6AB-46FB-4FD5-812C-C86E471821A4Q45953662-D15DA637-DFB8-470A-A3A0-87817403F85DQ46075838-871477A8-F182-4FDC-88D2-C2AE07442CEBQ46668112-205A549A-6F39-4DC5-8A51-5634CB116AA9Q47143000-1ABF2AEB-FD82-472B-8D99-5FCB02E73957Q47235995-03D55C53-30EC-4160-B8B8-A8A55A972B34Q48216103-DAEBA688-A115-47CD-A323-0EFC5812B499Q48260461-2AE2B460-382D-409D-AFBB-9D89AEB196AE
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Andrew C. Hooker
@ast
Andrew C. Hooker
@en
Andrew C. Hooker
@es
type
label
Andrew C. Hooker
@ast
Andrew C. Hooker
@en
Andrew C. Hooker
@es
prefLabel
Andrew C. Hooker
@ast
Andrew C. Hooker
@en
Andrew C. Hooker
@es
P214
P244
P106
P1153
9246529700
P21
P213
0000 0000 4536 7114
P214
P244
no2002027748
P2456
P31
P3835
andrew-hooker
P496
0000-0002-2676-5912
P735
P7859
lccn-no2002027748